Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
ScholarIQanswers from OpenAlex

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

PaperCitations, authors & open-access status

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 511 citations, 2023 year and green oa status.

511
Citations
2023
Year
green
OA Status

Related on ScholarIQ

Manabu Morimoto
Author
The Lancet
Journal
Hepatocellular Carcinoma Treatment and Prognosis
Topic
Hepatocellular Carcinoma Treatment and Prognosis
Topic
Cholangiocarcinoma and Gallbladder Cancer Studies
Topic
Liver Disease Diagnosis and Treatment
Topic
470M+ articles · free account